Phosphodiesterase 3 (PDE3)

Phosphodiesterase 3 (PDE3) is an enzyme that catalyzes the hydrolysis of cyclic nucleotides, specifically cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). It plays a crucial role in regulating intracellular concentrations of these important second messengers. PDE3 belongs to a family of phosphodiesterases (PDE1-PDE11) and comprises two subfamilies, PDE3A and PDE3B, which differ in tissue distribution. PDE3A is predominantly found in the cardiovascular system, platelets, and oocytes, while PDE3B is mainly expressed in adipose tissue, liver, and pancreas. The enzyme has a conserved catalytic core, regulatory N-terminus, and C-terminus, with the catalytic domain containing a unique 44-amino acid insert. Multiple isoforms exist for PDE3A (PDE3A-136, -118, -94), while PDE3B1 is the only identified human PDE3B isoform. PDE3 is involved in cardiovascular regulation, platelet aggregation, metabolic processes, and cell survival/apoptosis. It has high affinity for both cAMP and cGMP but higher Vmax for cAMP. PDE3 has been implicated in various diseases, including cardiovascular diseases, cancer, inflammatory conditions, and metabolic disorders. PDE3 inhibitors like milrinone, cilostazol, and levosimendan are used therapeutically for conditions like heart failure, intermittent claudication, and thrombocythemia. However, their long-term use in heart failure is associated with safety concerns, including increased mortality and arrhythmias. Emerging research includes exploring PDE3 as a cancer therapy target and novel targeting strategies beyond catalytic inhibition.

PDE3 inhibitors block the hydrolysis of cAMP and cGMP, leading to increased intracellular levels of cyclic nucleotides. This primarily increases cAMP levels and enhances protein kinase A (PKA) activity, which promotes vasodilation, increases cardiac contractility (positive inotropic effect), and inhibits platelet aggregation.